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S U M M A R Y
Objectives: TREAT, a decision support system for antimicrobial therapy, was implemented in an acute
medical ward.
Methods: Patients admitted on suspicion of infection were included in the study. The evaluation of
TREAT was done both retrospectively and prospectively. Coverage of empirical antimicrobial treatments
was compared to recommendations from TREAT and the optimal use of local guidelines.
Results: Five hundred and eleven patients were included, of whom 162 had a microbiologically
documented infection. In the retrospective part of the study, TREAT, physician, and guideline
antimicrobial coverage rates were 65%, 51%, and 79%, respectively, and in the prospective part, 68%, 62%,
and 77%, respectively. TREAT provided lower coverage than local guidelines (p < 0.001), but was similar
to the performance of physicians in a university hospital (p = 0.069). No differences were found in length
of hospital stay, or hospital or 30-day mortality. Direct costs were signiﬁcantly higher for TREAT advice
than for local guidelines or the physician prescriptions (p < 0.001), but the ecological costs were lower
for TREAT advice than for both local guidelines (p < 0.001) and physician prescriptions (p = 0.247). The
coverage of TREAT advice for the bacteraemia patients was non-inferior to the physicians (p = 1.00).
Conclusions: TREAT can potentially improve the ecological costs of empirical antimicrobial therapy for
patients in acute medical wards, but provided lower coverage than local guidelines.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
Contents lists available at ScienceDirect
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
TREAT is a computerized decision support system for antibiotic
treatment of common bacterial infections in hospitalized patients.
The program uses the local epidemiology regarding distribution of
pathogens and resistance patterns, and information about the
actual patients, such as age, gender, laboratory data, signs and
symptoms of infection, the presence of foreign devices, the
acquisition of infection, presumed infection foci, etc. The system
can be used at any decision point during the course of antibiotic
therapy and takes recent hospital admissions into account. The
current study addressed only empirical treatment.
The treatment proposals are based on assumptions of the most
likely pathogens, severity of the illness, and a balance of beneﬁts of* Corresponding author. Tel.: +45 3545 4048; fax: +45 3545 5362.
E-mail address: bentearboe@hotmail.com (B. Arboe).
http://dx.doi.org/10.1016/j.ijid.2014.08.019
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).antibiotic treatments and ecological and direct costs. The TREAT
system has been tested in three countries in a randomized
controlled trial,1 and has been shown to improve the percentage of
appropriate empirical antibiotic treatments and reduce the length
of hospital stay and the use of broad-spectrum antibiotics.
This article outlines the performance of the TREAT system in a
new and updated version, in an acute medical ward of a university
hospital in Copenhagen, Denmark. In this updated version with
dropdown menus, organ-speciﬁc panels, and automatic incorpo-
ration of laboratory data, the screen time is shortened to less than
10 min per patient. TREAT has not previously been tested in an
acute medical ward or in an environment of low bacterial
resistance.
2. Materials and methods
The TREAT system has been developed by the Centre for Model-
Based Medical Decision Support, Aalborg University, and Treatciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
B. Arboe et al. / International Journal of Infectious Diseases 29 (2014) 156–161 157Systems, Aalborg, Denmark (http://www.treatsystems.dk). The
system is a causal probabilistic network and gives a proposal of
antimicrobial treatment or no treatment based on the information
given. It weighs beneﬁts of a treatment with both the direct and the
ecological costs. The ﬁgures used for the ecological costs are given
in Table 1. Ecological costs are calculated as drug-speciﬁc constants
using assumptions of costs if resistance occurs.
The TREAT system can be integrated into the hospital informa-
tion technology (IT) system and it imports the laboratory data
directly. Data including age, gender, total leukocyte counts,
neutrophil leukocyte counts, haemoglobin, platelets, C-reactive
protein (CRP), sodium, potassium and microbiological ﬁndings
during the previous 7 days are automatically incorporated into the
decision-making. The physician should manually enter other patient
data, such as background conditions, history of the illness, recent
hospital admissions, signs and symptoms, and radiology ﬁndings.
3. Setting
The acute medical ward at Hvidovre Hospital (medical
emergency ward) was used as a test facility. Copenhagen
University Hospital, Hvidovre Hospital, is a 600-bed hospital for
acute internal medicine diseases with a catchment area of
approximately 400 000 inhabitants. The Department of Clinical
Microbiology at Hvidovre Hospital serves a catchment area of more
than 800 000 inhabitants, and the entire microbiological database
on specimens, species, and susceptibility data were used to
calibrate the TREAT database. Hence the calibration takes account
of both hospital- and community-acquired infections. During the
retrospective part of the study a new version of TREAT was
calibrated, and this new, updated version was used to evaluate
both the retrospective and the prospective data.
3.1. Study design
The study was designed as a retrospective and a prospective
cohort study. The retrospective part included patients admittedTable 1
Cost of treatment
Generic name Direct costs, in E
Penicillin IV and PO 16.6; 0.2 
Amoxicillin PO 0.7 
Amoxicillin–clavulanic acid PO 0.5 
Ampicillin IV and PO 9.5; 9.5 
Pivmecillinam PO 0.4 
Dicloxacillin IV and PO 5.1; 2.5 
Piperacillin–tazobactam IV 31.6 
Cefuroxime IV; ceftriaxone IV; ceftazidime IV 1.4; 6.3; 20.3 
Ertapenem IV; meropenem IV 47.1; 21.3 
Gentamicin IV 3.7 
Nitrofurantoin PO 0.4 
Vancomycin IV and PO 32.7; 16.7 
Clarithromycin IV and PO 21.7; 1.0 
Clindamycin IV and PO 6.4; 1.7 
Linezolid IV and PO 87.7; 131.3 
Moxiﬂoxacin IV and PO 49.7; 3.8 
Ciproﬂoxacin IV and PO 2.3; 0.2 
Tigecycline IV 152.0 
Trimethoprim–sulfamethoxazole 11.7; 1,4 
Trimethoprim PO 0.2 
Metronidazole IV and PO 2.1; 0.8 
Fluconazole IV and PO 2.6; 0.2 
Voriconazole IV and PO 307.6; 115.4 
Posaconazole PO 119.3 
Caspofungin IV; anidulafungin IV 526.3; 502.5 
Amphotericin B liposomal IV 125.6 
Aciclovir IV and PO 50.1; 49.6 
PO, per oral; IV, intravenously.
a See text for further details.from December 2010 to February 2011. Information available at
admission was entered into the program. The advice of TREAT had
no effect on the choice of treatments.
In the prospective part, patients with infection or signs or
symptoms of systemic inﬂammation were included from Novem-
ber 2011 to April 2012. Patients were included at admission to the
acute medical ward. The physicians were asked to use TREAT in
real time, and the physician responsible for the patient’s treatment
was free to follow or not follow the advice from TREAT. All
physicians also had access to paper versions of the local guidelines
of the acute medical ward.
Outcome parameters were appropriateness of empirical
antimicrobial treatment to the group of patients with microbio-
logically conﬁrmed infections regarding the TREAT advice, the
treatment chosen by physicians, and the treatment recommended
by the local guidelines. Length of stay, hospital mortality, and 30-
day mortality were measured.
Evaluation of the treatment given and the TREAT advice was
done by a senior clinical microbiologist, a senior infectious diseases
specialist, and two junior physicians. Two senior clinical micro-
biologists made an external evaluation.
3.2. Patients included in the study
Patients older than 16 years admitted to the acute medical ward
could be included if the examining physician suspected an
infection, or if systemic antimicrobial therapy was initiated. The
Centers for Disease Control and Prevention (CDC) criteria for
infection were used when evaluating the cases. These include the
systemic inﬂammatory response syndrome (SIRS) criteria (body
temperature 38 or <36 8C, heart rate >90/min, respiratory rate
>20/min, partial pressure of CO2 <32 mmHg, and white blood cell
count >12  109/l or <4  109/l, or >10% immature (band) forms)
and septic shock deﬁned as hypotension (arterial blood pressure
<90 mmHg systolic or 40 mmHg less than the patient’s normal
blood pressure) for at least 1 h despite adequate ﬂuid resuscitation,
or the need for vasopressors to maintain systolic blood pressureuro per day of treatment Ecological costs, in Euro per daya
4.4
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source of infection.
Patients could be included for each episode fulﬁlling the
inclusion criteria, if each episode was separated by a minimum of
7 days and a minimum of two afebrile days. Each case was
evaluated as an unrelated episode.
Patients with a diagnosed HIV infection, travel-related infec-
tion, and cases of suspected tuberculosis, were excluded. Pregnant
women were also excluded. Patients were included if the physician
used TREAT, whether or not the advice was followed.
3.3. Statistical analysis
Dichotomous outcomes were compared using the Chi-square
test or Fisher’s exact test, as appropriate. p-Values below 0.05 were
considered statistically signiﬁcant.
4. Results
The characteristics of the patients included are shown in
Table 2. In total, 511 patient cases were included, 248 in the
retrospective part and 263 in the prospective part of the study.
Eighty (32.3%) cases in the prospective part and 82 (33.1%) in the
retrospective part had microbiologically evaluable infections.
The internal panel of experts easily agreed on the evaluation of
TREAT advice, the treatment given by the physicians, and the
optimal use of the local guidelines. The external experts conﬁrmed
the evaluation. The results are summarized in Table 3.
In the retrospective part, physicians prescribed appropriate
empirical treatment in 51.3% (41/80) of the cases and TREAT
advised appropriate empirical treatment for 65% (52/80) of the
cases (p = 0.109). The local guidelines advised appropriate
empirical treatment in 78.8% (63/80) of the cases.
In the prospective part, physicians prescribed appropriate
empirical treatment in 62.2% (51/82) of the cases. TREAT advised
appropriate empirical treatment in 68.3% (56/82) of the cases. The
local guidelines advised appropriate empirical treatment in 76.8%
(63/82) of the cases.
When analyzing the retrospective and prospective data
together, the coverage of TREAT was inferior to the local guidelines
(p < 0.001), but not signiﬁcantly different from the physician
prescriptions (p = 0.069).
There were no differences in direct or ecological costs between
the retrospective and the prospective parts of the study for the
local guidelines, physician prescription, or the TREAT advice.
Analyzed together, the direct costs for the guidelines, physician
choice, and TREAT advice were a median 1.4, 1.4, and 7 Euro/day,
respectively. TREAT advice was signiﬁcantly more expensive than
both the local guidelines and physician choice (p = 0.002). The
median ecological costs of the local guidelines, physician choice,
and TREAT were 491, 492, and 196 Euro/day, respectively. TREAT
was signiﬁcantly less expensive (p-values <0.001).
Fourteen patients with signiﬁcant bacteraemia were identiﬁed
in the retrospective part. TREAT advised appropriate empirical
treatment for 86% (12/14) and the physicians prescribed appro-
priate empirical treatment for 57% (8/14) (p = 0.121). The local
guidelines advised appropriate empirical treatment in 93% (13/14)
of the cases. None of the six patients treated with non-covering
antimicrobial therapy died during hospitalization or within
30 days.
In the prospective part, TREAT advised appropriate empirical
treatment to 74% (14/19) of patients with signiﬁcant bacteraemia
and the physicians prescribed appropriate empirical treatment to
79% (15/19) (p = 1.00). The local guidelines advised appropriate
empirical treatment in 95% (18/19) of the cases. Two patients were
not given covering empirical treatment and died after 1 and 5 days,
T
a
b
le
3
T
re
a
tm
e
n
t
co
v
e
ra
g
e
M
ic
ro
b
io
lo
g
ic
a
l
ﬁ
n
d
in
g
s
P
a
ti
e
n
ts
,
n
(%
)
C
o
v
e
ra
g
e
b
y
lo
ca
l
g
u
id
e
li
n
e
s,
n
(%
)
C
o
v
e
ra
g
e
b
y
p
h
y
si
ci
a
n
s,
n
(%
)
C
o
v
e
ra
g
e
b
y
T
R
E
A
T
,
n
(%
)
Le
n
g
th
o
f
h
o
sp
it
a
l
st
a
y
,
d
a
y
s,
m
e
d
ia
n
(r
a
n
g
e
)
H
o
sp
it
a
l
m
o
rt
a
li
ty
,
n
(%
)
3
0
-d
a
y
m
o
rt
a
li
ty
,
n
(%
)
D
ir
e
ct
co
st
sa
G
u
id
e
,
s
/d
a
y
,
m
e
d
ia
n
(r
a
n
g
e
)
D
ir
e
ct
co
st
sa
P
h
y
si
ci
a
n
,
s
/d
a
y
,
m
e
d
ia
n
(r
a
n
g
e
)
D
ir
e
ct
co
st
sa
T
R
E
A
T
a
d
v
ic
e
,
s
/d
a
y
,
m
e
d
ia
n
(r
a
n
g
e
)
E
co
lo
g
ic
a
l
co
st
s
G
u
id
e
a
,
s
/d
a
y
,
m
e
d
ia
n
(r
a
n
g
e
)
E
co
lo
g
ic
a
l
co
st
s
P
h
y
si
ci
a
n
a
,
s
/d
a
y
,
m
e
d
ia
n
(r
a
n
g
e
)
E
co
lo
g
ic
a
l
co
st
s
T
R
E
A
T
a
d
v
ic
e
a
,
s
/d
a
y
,
m
e
d
ia
n
(r
a
n
g
e
)
R
e
tr
o
sp
e
ct
iv
e
st
u
d
y
(n
=
2
4
8
)
Y
e
s
8
0
3
2
.3
%
6
3
7
8
.8
%
4
1
5
1
.3
%
5
2
6
5
.0
%
6
.5
(1
–
6
1
)
1
1
1
3
.8
%
1
3
1
6
.2
1
.4
(0
–
3
5
)
1
.4
(0
–
3
2
)
9
.4
b
(0
–
6
2
)
4
9
1
(0
–
1
3
2
2
)
4
9
2
(0
–
9
0
4
)
1
9
6
c
(0
–
6
0
5
)
N
o
1
6
8
6
7
.7
%
N
D
N
D
N
D
4 (1
–
6
0
)
1
8
1
0
.7
%
2
7
1
6
.1
%
N
D
N
D
N
D
N
D
N
D
N
D
P
ro
sp
e
ct
iv
e
st
u
d
y
(n
=
2
6
3
)
Y
e
s
8
2
3
3
.1
%
6
3
7
6
.8
%
5
1
6
2
.2
%
5
6
6
8
.3
%
5 (1
–
1
0
4
)
9
1
1
.0
%
1
1
1
3
.4
%
1
.4
(0
–
2
4
)
1
.4
(0
–
2
1
)
1
.9
b
(0
–
5
0
)
4
9
1
(0
–
1
3
2
2
)
4
9
2
(0
–
9
0
9
)
1
9
7
c
(0
–
6
9
6
)
N
o
1
8
1
7
3
.0
%
N
D
N
D
N
D
4 (1
–
4
6
)
1
0
5
.5
%
1
5
8
.3
%
N
D
N
D
N
D
N
D
N
D
N
D
T
o
ta
l
5
1
1
(1
0
0
%
)
1
2
6
7
7
.8
%
9
2
5
6
.8
%
1
0
8
6
6
.7
%
5 (1
–
1
0
4
)
4
8
9
.4
%
6
6
1
2
.9
%
1
.4
(0
–
3
5
)
1
.4
(0
–
3
2
)
7
b
(0
–
6
2
)
4
9
1
(0
–
1
3
2
2
)
4
9
2
(0
–
9
0
9
)
1
9
6
c
(0
–
6
9
6
)
N
D
,
n
o
d
a
ta
.
a
S
e
e
T
a
b
le
1
fo
r
d
e
ta
il
s.
b
T
h
e
a
ct
u
a
lc
o
st
s
fo
r
tr
e
a
tm
e
n
ts
re
co
m
m
e
n
d
e
d
b
y
T
R
E
A
T
b
o
th
in
th
e
p
ro
sp
e
ct
iv
e
a
n
d
th
e
re
tr
o
sp
e
ct
iv
e
p
a
rt
,a
n
d
w
h
e
n
a
n
a
ly
se
d
to
g
e
th
e
r,
w
e
re
si
g
n
iﬁ
ca
n
tl
y
h
ig
h
e
r
th
a
n
fo
r
th
e
tr
e
a
tm
e
n
ts
re
co
m
m
e
n
d
e
d
b
y
th
e
lo
ca
lg
u
id
e
li
n
e
s
o
r
th
e
tr
e
a
tm
e
n
t
b
y
th
e
p
h
y
si
ci
a
n
s,
p
-v
a
lu
e
s
<
0
.0
0
1
.
c
T
h
e
e
co
lo
g
ic
a
l
co
st
s
fo
r
th
e
T
R
E
A
T
a
d
v
ic
e
b
o
th
in
th
e
p
ro
sp
e
ct
iv
e
a
n
d
th
e
re
tr
o
sp
e
ct
iv
e
p
a
rt
,a
n
d
w
h
e
n
a
n
a
ly
se
d
to
g
e
th
e
r,
w
e
re
si
g
n
iﬁ
ca
n
tl
y
lo
w
e
r
th
a
n
fo
r
th
e
tr
e
a
tm
e
n
ts
re
co
m
m
e
n
d
e
d
b
y
th
e
lo
ca
l
g
u
id
e
li
n
e
s,
p
-v
a
lu
e
s
<
0
.0
0
1
,
a
n
d
a
ls
o
si
g
n
iﬁ
ca
n
tl
y
lo
w
e
r
th
a
n
th
e
tr
e
a
tm
e
n
t
b
y
p
h
y
si
ci
a
n
s,
p
-v
a
lu
e
s
<
0
.0
2
5
.
B. Arboe et al. / International Journal of Infectious Diseases 29 (2014) 156–161 159respectively, the latter one after adjustment to covering therapy.
The TREAT advice for these patients was not appropriate either.
The empirical coverage for bacteraemic patients was not
signiﬁcantly different in the two parts of the study (p = 0.257).
For patients with a microbiologically documented infection,
CRP values were signiﬁcantly higher in both the retrospective and
the prospective parts of the study (p < 0.001 and p = 0.0162,
respectively) (Table 2). No differences in leukocyte counts or body
temperature were found. No differences in length of hospital stay,
hospital mortality, or 30-day mortality rates were seen between
the groups of patients in the retrospective or the prospective parts
of the study (Table 3).
A total of 271 patients had pneumonia or exacerbation of
chronic obstructive pulmonary disease (COPD), of whom 81 (39%)
had microbiological veriﬁcation. Ninety-two patients had a urinary
tract infection, of whom 63 (68%) had microbiological veriﬁcation,
and 41 patients (27%) had a skin and soft tissue infection, of whom
11 had microbiological veriﬁcation. Eighty-seven of the patients
with no microbiologically documented infection were discharged
with a non-infectious diagnosis.
Table 4 shows the patients divided according to the appropri-
ateness of the antimicrobials given and further divided into groups
according to the advice given by TREAT. No difference in outcome
as a result of covering empirical treatment given could be detected.
The group of patients receiving covering empiric treatment, but
who were not covered by TREAT advice, had a particularly
favourable outcome with no deaths during hospitalization or
within 30 days, and only an average 3 days of hospitalization
(Table 3). Although not signiﬁcantly different from the other
groups, this group may represent patients suffering from relatively
mild infections. Among the 33 patients with signiﬁcant bacter-
aemia, 23 (70%) received covering empirical treatment. TREAT
advice would have covered 26 (79%) patients. Among the
bacteraemic patients, four died during hospitalization and ﬁve
within 30 days after admission, and two of these patients did not
have empirical coverage.
The advice from TREAT and the empirical treatment given to
bacteraemic patients differed in 93% (13/14) of cases in the
retrospective part of the study and in 42% (8/19) in the prospective
part of the study, i.e., consistency was signiﬁcantly higher in the
prospective part (p = 0.009).
The 30-day mortality rate was slightly higher in the retrospec-
tive part of the study (40 of 248) than in the prospective part (26 of
263) (p = 0.047); the reason for this is not clear.
To evaluate the TREAT system user interface, a study of login
times showed that a new user of the TREAT system took 5–6 min
for data entry per patient and a more experienced user took 2–
3 min (TREAT Systems, data not shown).
5. Discussion
The present study demonstrated TREAT to be non-inferior to the
performance of physicians in an acute medical ward of a university
hospital, and we found no signiﬁcant difference when evaluating
the patients with microbiological ﬁndings (p = 0.069). The results
of the retrospective and the prospective parts were consistent, and
also consistent with those of other studies, where the empirical
antimicrobial treatment of clinical physicians had a coverage of
50–65%.1,2 It is important to emphasize that this is an average
ﬁgure and does not necessarily reﬂect the treatment of critically ill
patients, such as patients with meningitis, bacteraemia, etc. TREAT
has been shown to increase the overall empirical coverage of
antimicrobial treatment in other settings.1 The model did not
include ecological costs for antifungal therapy, nor for resistance to
antifungal agents, but as we are mainly discussing the empirical
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antifungal therapy are absolutely minor.
The results in Tables 3 and 4 show that mortality in the
microbiologically evaluable patients was higher in the retrospec-
tive part of the study than in the prospective part, both for patients
who received covering empirical antimicrobial therapy and those
receiving therapy that was not covering. This cannot be explained
by a difference in antibiotic prescription, and no other obvious
reason was found. One can speculate that more focus may have
been placed on the empirical treatment in the underlying period,
but this cannot explain the higher mortality in patients receiving
covering treatment. In the retrospective part, all patients with
microbiological ﬁndings were included, whereas in the prospective
part, we only included patients for whom TREAT was used. This
may have caused a selection bias if physicians, in order to save
time, did not use TREAT for critically ill patients when time was
critical. This may also explain why the outcome in the prospective
part was better for patients with treatment that was not covering
(15.2% vs. 11.3%; Table 4).
TREAT has been tested prospectively in areas with a high
prevalence of resistant pathogens in a randomized controlled trial
and signiﬁcantly improved the empirical antimicrobial treatment
(70% vs. 57%, p < 0.001).1 TREAT has also been shown to be able to
predict bacteraemia and divide patients into low risk, intermediate
risk, and high risk groups,3 and to predict bacteraemia in patients
in our setting.4 Furthermore, it has shown the capability to predict
the speciﬁc pathogens causing infection.5
By using a decision support system it is possible to guide young
physicians in particular in the appropriate use of antimicrobial
agents. It is also possible to implement shifts in antimicrobial
policy, e.g., new guidelines, emergence of special antimicrobial
resistance, or outbreaks of particular microorganisms. The system
was developed to make a model taking all factors into consider-
ation, i.e. the local distribution of pathogens, the susceptibility
patterns of these pathogens, and the clinical presentation of the
patient.6
When using the TREAT program, physicians are asked questions
about the patient’s background, clinical status, travel history, and
exposure to resistant microorganisms. Therefore the program can
ensure a thorough examination of the patient and it can produce a
resume page providing a comprehensive view of the patient case. It
is important to emphasize that the program only provides
suggestions for treatment. The physician has the responsibility
and makes the ﬁnal decision.
In the present study, TREAT was inferior to optimal adherence
to the local guidelines (p = 0.035). The lack of input of clinical signs
and symptoms might impair the performance of the system. Our
physicians were asked to use TREAT at the time of admission and
consider the recommendations in their choice of treatment, but the
ﬁnal choice of treatment was theirs.
During the prospective study period it became clear that the
physicians did not use TREAT routinely. TREAT was introduced
through lectures in groups of 20, and throughout the implemen-
tation phase, informal one-on-one help was available. Despite
this, implementation needed considerable time and continuous
education. This reﬂects the fact that while including a total of
248 patients in the retrospective part for 3 months, the inclusion of
263 patients in the prospective part lasted 6 months. Since the use
or non-use of TREAT was equally distributed between all patients
admitted during the period, we believe that this did not alter the
demographic characteristics of the patients included.
The implementation also showed an extended need for
workstations, which is well known as a limiting factor when
introducing new healthcare information technologies.7 After some
initial reluctance, the experience showed the systems to be quite
fast and possibly helpful.
B. Arboe et al. / International Journal of Infectious Diseases 29 (2014) 156–161 161Different approaches can be made to improve empirical
antimicrobial treatment. One strategy is the implementation of
a decision support system such as the one described here. We
found that in our setting, the optimal use of the local guidelines
would have provided an even higher empirical coverage. It is not
uncommon for adherence to local guidelines to be problematic,
even though guidelines are easily accessible, written in a precise
way, and education is provided.8 It has been shown that if local
guidelines are followed, patient outcomes improve.9,10 In sepsis
patients, non-adherence to guidelines can result in more broad-
spectrum treatment but not more appropriate treatment.11
In other settings it has been shown that including physicians in
the development of local guidelines and thereby giving them
responsibility and ownership, facilitates adherence to local
guidelines.12 Other strategies are the combination of intense
education, feedback, and evaluation, or the introduction of a simple
monitoring form that increases the focus on prescription and the
use of antimicrobial treatment.13,14
In the present study we only implemented a decision support
system and provided education on the use of the system, but no
other interventions were carried out to improve the empirical
antimicrobial treatment.
In conclusion, TREAT did not provide a higher coverage of
empirical antimicrobial treatment for patients in our acute medical
ward than the physicians at the university hospital. We measured
the clinical impact in terms of length of stay, hospital mortality,
and death within 30 days. The numbers are too small to draw any
ﬁnal conclusions, but we were not able to document any
improvements using the TREAT system. We found that adherence
to the local guidelines would have provided even higher coverage
than the TREAT advice in our study. Future larger studies are
required to test the use of a decision support system for
antimicrobial treatment in an acute medical ward.
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